A multi-omics features-based approach integrating immunogenicity and inflammation enhances immunotherapy benefit in clear cell renal cell carcinoma

We propose a TIs-ML prediction model based on multi-omics features that can effectively predict ICB treatment response in ccRCC patients. The model integrates inflammatory and immune features, and its high generalization ability was validated in multiple cohorts. Overall, the TIs-ML approach provides a novel method for guiding precise immunotherapy in ccRCC.